Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
Gyala Therapeutics
Gyala Therapeutics
Memorial Sloan Kettering Cancer Center
Indiana University
Children's Hospital of Philadelphia
French Innovative Leukemia Organisation
AVM Biotechnology Inc
Essen Biotech
University of Milano Bicocca